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Abstract
Introduction: The coexistence of allergic bronchopulmonary aspergillosis and aspergilloma is rare.
Case presentation: We present the case of a 56-year-old Caucasian man who worked as a farmer, with infiltrates
in the right lower and middle lung lobes, partial consolidation of the middle lobe and with previous diagnosis of
chronic obstructive bronchitis. Evaluation of our patient led to the diagnosis of allergic bronchopulmonary
aspergillosis with coexistent aspergilloma in the right lower lobe. He was treated with oral methylprednisolone and
itraconazole. At the five-year follow-up he is without any sign of recurrence.
Conclusion: Aspergillus infection after the inhalation of spores in the form of a hypersensitivity reaction and
saprophytic colonization can be coexistent.
Introduction
Allergic bronchopulmonary aspergillosis (ABPA) is a
complex hypersensitivity reaction in patients with
asthma, which occurs when bronchi are colonized by
the fungus Aspergillus, most often Aspergillus fumigatus.
The disease is characterized by type I and type III
hypersensitivity reactions. The incidence may be as high
as 6% of patients with asthma [1]. Repeated episodes of
bronchial obstruction, inflammation and mucoid impac-
tion can lead to bronchiectasis, fibrosis and respiratory
compromise.
Aspergilloma is a saprophytic growth of fungus,
usually A. fumigatus, in the lumen of an existing cavity,
which does not invade the tissue. Fungus ball formation
has been observed in an old tuberculosis cavity, bronch-
iectasis, abscess or in a congenital cyst.
We present a case of the coexistence of ABPA and
aspergilloma. A patient with ABPA developed a cavitary
pulmonary lesion with characteristic radiological appear-
ances of aspergilloma. The management and time
sequence of the ABPA and aspergilloma occurrences are
discussed.
Case presentation
A 56-year-old Caucasian Slovenian man, who worked as
a farmer and was a non-smoker, was treated for bronch-
opneumonia in the right upper lobe in 1970 and 1974.
The infiltrate resolved after antibiotic therapy with peni-
cillin. He also had symptoms of chronic bronchitis, but
he did not require therapy.
In 1996, our patient presented with persistent cough,
dyspnea and sweats. He had no fever. A general practi-
tioner prescribed him a macrolide antibiotic, but there
was no response to this treatment and our patient was
referred to a pneumologist. A chest radiograph showed
an infiltrate with cavitation in the right lower lobe. Spu-
tum testing for tuberculosis was negative. Tuberculine
testing was positive and our patient received tuberculo-
static therapy without any improvement over the follow-
ing four weeks.
On admission to our hospital, he was afebrile and
eupnoic. No lymphadenopathy was found. At the aus-
cultation, prolonged expiration and weaker lung sounds
over the right basal field were heard. A chest radiograph
showed the infiltrates with cavitation in the right lower
lobe and in the middle lobe with consolidation of the
latter (Figure 1). Laboratory data showed an elevated
erythrocyte sedimentation rate of 66 mm/h and a nor-
mal white cell count. Pseudomonas aeruginosa was iso-
lated from the sputum and our patient was treated with
ciprofloxacin. Pulmonary function tests showed reduced
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forced vital capacity (FVC) of 2900 mL (-36%), reduced
forced expiratory volume in the first second (FEV1) of
1900 mL (-40%), with the Tiffeneau index of 65%. Arter-
ial blood gas analysis showed only mild hypoxemia (pO2
9.5 kPa). We also performed fiberbronchoscopy and
found a necrotic and purulent mass in the middle lobe
bronchus that had practically closed the lumen. Cytolo-
gical examination of the material obtained with
bronchial brushing disclosed numerous eosinophils,
Charcot-Leyden crystals and fungal structures morpholo-
gically corresponding to Aspergillus spp. (Figure 2).
There were no malignant cells. Histological examination
of the bronchial biopsy specimen showed chronic inflam-
matory changes in bronchial mucosa with mononuclear
cells and focally granulocytes infiltration. Control fiber-
bronchoscopy after one week revealed inflammatory infil-
tration of mucosa in the middle lobe bronchus.
Histopathology showed non-specific inflammatory
changes of bronchial mucosa. Cutaneous testing for the
A. fumigatus antigen was strongly positive. Total serum
immunoglobulin E (IgE) concentration was elevated
(505 IU/mL), specific IgE against A. fumigatus were
strongly elevated (27.9 IU/mL). Serum precipitating
antibodies were elevated, specific IgG against A. fumiga-
tus (55 IU/mL) and against A. flavus (51 IU/mL). Meta-
choline bronchoprovocation testing showed bronchial
hyper-responsiveness with the reversibility of obstruction
after the bronchodilator. Our patient received methyl-
prednisolone, 32 mg daily. The dose was gradually
tapered during the subsequent months.
Pulmonary function tests improved: FVC from 2900
mL to 3100 mL and FEV1 from 1900 mL to 2200 mL.
Total serum IgE concentration fell to 186 IU/ml, speci-
fic IgE against A. fumigatus to 6.1 IU/ml, specific IgG
precipitating antibodies against A. fumigatus and
A. flavus fell to 30 IU/mL and 32 IU/mL, respectively.
The chest radiograph disclosed that the infiltrate in
the middle lobe resolved, but in the posterior segment
of the right lower lobe a cavitary pulmonary lesion
with the diameter of 3 cm and with an air crescent
was formed. The radiological appearances of this lesion
were characteristic of an aspergilloma (Figure 3). Itra-
conazole 200 mg daily for two months was added to
methylprednisolone.
Subsequent controls showed further clinical improve-
ment. The chest radiographs and chest computed
Figure 1 Chest radiograph showing an infiltrate with a cavitation in the right lower and middle lobes.
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Figure 2 Fungal hyphae morphologically corresponding to Aspergillus sp. May Grunwald-Giemsa (MGG) staining, original
magnification × 400.
Figure 3 A cavitary lesion with air crescent in the right lower lobe seen on chest radiograph is characteristic of an aspergilloma.
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tomography (CT) showed that the aspergilloma became
smaller, measuring 2 cm in diameter, and was partially
calcified. Fibrotic changes in the right lower and middle
lobes were present. Chest CT also showed tram-line
shadows of bronchial wall thickening and cylindrical
bronchiectasis in the middle lobe (Figure 4). Specific IgE
against A. fumigatus remained elevated (9.4 IU/mL)
while specific IgG precipitating antibodies against
A. fumigatus and A. flavus normalized (7 IU/mL and
19 IU/mL, respectively). Our patient receives inhalatory
steroid and short-acting b2-agonist. He is being followed
over a five-year period with no signs of recurrence.
Discussion
The coexistence of an aspergilloma and ABPA is a rare
finding. Some authors described a development of
aspergilloma secondary to ABPA [2-4], and others
reported ABPA consequent to aspergilloma [5,6]. In
1973 Safirstein described an occurrence of aspergilloma
consequent to ABPA [4]. Israel (1980) reported the
rapid development of aspergilloma secondary to ABPA
with a brief history of preceding asthma [5]. Shah
reported, in 1989, two patients with ABPA who later
developed aspergillomas and were followed over 30 and
18 months, respectively [6]. In 1979, Ein et al. reported
two patients with an ABPA-like syndrome consequent
to aspergilloma with subjective and objective improve-
ments after the administration of corticosteroid therapy
[7]. Rosenberg (1984) described a patient with such a
combination followed over a two-year period [8]. Our
patient has been followed over five years and has not
shown signs of recurrence which can occur after many
years of remission [9].
In 1991, Hefti described a patient with ABPA and
aspergilloma in the left upper lobe following a chronic
abscessed pneumonia [10]. Shah reported a patient with
ABPA and with a middle lobe syndrome [11]. Our
patient had some symptoms of obstructive pulmonary
disease as early as in 1970, but his dyspnea was not
severe and he did not take any therapy. After under-
going bronchopneumonia in 1970 and 1974, only small
fibrotic changes were seen on chest radiographs of the
right upper lobe of the lung. There was no pathology in
the middle or right lower lobes. Thus, at that time, no
pulmonary cavities were described where aspergilloma
formation could grow. Pulmonary tuberculosis was
never proven. Nevertheless, on admission into our hos-
pital in August 1996, a cavity was suggested inside the
infiltrate in the right lower lung (Figure 1), which was
not seen on the chest radiographs from 1970. It is possi-
ble that in 26 years, a cavitary lesion developed where
aspergilloma later occurred. The patient had a pulmon-
ary infiltrate in the right lower lobe with endobronchial
obstruction of the middle lobe bronchus by an impacted
mucus plug. Later, a CT-scan showed cylindrical
bronchiectasis of the middle lobe and aspergilloma in
the right lower lobe.
This patient was a farmer and therefore his exposure
to an environment rich in the Aspergillus spores was
high. Vernon et al. found that patients with ABPA had
not been more exposed to potentially rich sources of
A. fumigatus than atopic control patients. Specific host
susceptibility seems to be more important in the
pathogenesis of ABPA than environmental factors.
However, once the patient is sensitized a minor
increase in spore concentration can cause symptomatic
disease [12]. The presence of the type I hypersensitivity
described in some patients with aspergilloma suggests
an immunologic component to this disease which
could contribute to a chronic inflammatory response
to Aspergillus.
Oral corticosteroids are the therapy of choice in
ABPA. Itraconazole may have its role in therapy, espe-
cially in cases where oral corticosteroids are contrain-
dicated. In patients requiring high doses of oral
steroids itraconazole may allow a reduction in dose,
but should not replace the need of corticosteroid treat-
ment [1]. Corticosteroid treatment should result in the
reduction of the IgE level (remission or stage II dis-
ease). Resolution of pulmonary infiltrates and clinical
improvement are generally accompanied by at least a
35% reduction in serum total IgE, which was seen also
in our patient. He was treated with oral methylpredni-
solone for four months. Itraconazole 200 mg daily was
added for two months after the resolution of the infil-
trate when the aspergilloma in the right lower lobe
became visible.
Figure 4 Computed tomography revealed tram-line shadows
and cylindrical bronchiectasis in the middle lobe.
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Conclusions
We conclude that in a patient with ABPA who develops
a cavitary lesion, aspergilloma should be considered.
The time sequence of ABPA and aspergilloma occur-
rence can also be reversed. After corticosteroid and itra-
conazole treatment both subjective and objective
improvements are experienced.
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